Breaking News

Fujifilm Expands Gene Therapy Capabilities

Investing $55mn in gene therapy process and analytical development capabilities with the addition of new dedicated laboratories.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies (FDB), a global biologics contract development and manufacturing organization (CDMO), is expanding its gene therapy services with the addition of dedicated process and analytical development laboratories. As a part of a capital investment of approximately 13 billion yen (approx. $120 million USD) in the gene therapy field by Fujifilm Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters